Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment Topline results for both UC and CD now anticipated in Q4 2024 Teva and Sanofi ...

Xencor (NASDAQ:XNCR) used a webcast during Digestive Disease Week 2026 to highlight Phase I results for its TL1A-targeting monoclonal antibody XmAb942 and to outline preclinical data supporting ...

DelveInsight's TL1A Binder Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In recent years, a range of advanced therapies have been ...

Enhanced image showing where genes are active in colon tissue, revealing neutrophils located close to pre-cancerous epithelial cells [Longman Lab] It is known that inflammatory bowel disease (IBD) ...

PHOENIX — Duvakitug, a novel anti-TL1a monoclonal antibody, demonstrated statistically significant differences in endoscopic response rates compared to placebo in adults with moderately to severely ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...

AbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel disease (IBD) candidate.

The tumor necrosis factor (TNF) superfamily protein TNF-like 1A (TL1A) is the ligand for death receptor 3 (DR3). TL1A is induced on activated dendritic cells (DCs) and its expression has been linked ...

Your lungs and airways need to be stretchy, sort of like balloons. Take a big breath, and they'll open right up. Damaged lungs can't open properly. Patients with asthma, idiopathic pulmonary fibrosis ...